Neuland Laboratories Limited reported a net profit of ₹147.4 crore for the quarter ended June 30, 2026, marking a 975% surge from ₹13.7 crore in Q1FY26. The Hyderabad-based pharmaceutical manufacturer saw total income rise 116.3% year-on-year (YoY) to ₹650.1 crore, driven by robust performance across its Custom Manufacturing Services (CMS) and Generic Drug Sales (GDS) segments. This significant turnaround underscores the company’s operational leverage as it scales production capabilities, with EBITDA climbing 448.2% to ₹231.1 crore.

The filing, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights a sharp expansion in profitability metrics. Profit before tax (PBT) increased 1,036.7% to ₹197.5 crore, demonstrating effective cost management alongside revenue growth. Earnings per share (EPS) stood at ₹114.9, up from ₹10.7 in Q1FY26. While quarterly figures showed a sequential decline due to seasonal variations, the year-on-year comparison reveals substantial growth in underlying business health.

Financial Performance Overview

Business Segment Highlights

The CMS segment saw revenues driven by commercial molecules, with growth in new project orders expected to be delivered over this and next financial years. There is notable traction from innovators with peptide molecules in the pipeline. In the GDS segment, Ezetimibe and Mirtazapine were key molecules in the Prime segment, with Ezetimibe likely to drive future growth. The Specialty business was driven by Aripiprazole Sterile, Donepezil, and Apixaban.

Balance Sheet and Working Capital

Working capital days of sale improved significantly to 84 days in Q1FY27, down from 137 days in Q4FY26, mainly due to a decrease in receivables. Capex outflow stood at ₹122 crore in Q1FY27. Net debt increased to ₹308.5 crore as of June 30, 2026, compared to ₹164.7 crore in Q1FY26 and ₹156.8 crore in Q4FY26. Shareholder funds rose to ₹2,013.2 crore from ₹1,865.9 crore in March 2026.

What the Numbers Show

The divergence between revenue growth and profit expansion is notable. While total income grew 116.3% YoY, net profit surged 975%. This disproportionate rise suggests significant operating leverage, where fixed costs are spread over a larger revenue base, boosting margins. The EBITDA margin expansion of 2,150 basis points further confirms improved operational efficiency. However, the QoQ decline in both income and profit indicates potential seasonality or one-off factors in the previous quarter that inflated those numbers, making the YoY comparison more reflective of underlying business health. Management notes that investment intensity will likely increase based on available opportunities to build customer confidence.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE794A01010/d9d252d9-3fba-4f1f-bc61-e3a4d9ae752a.pdf

Neuland Laboratories Limited shareholders approved a final dividend of ₹34 per equity share for the financial year ended March 31, 2026, during its 42nd Annual General Meeting (AGM) held on August 4, 2026. The resolution received unanimous support from voting shareholders, with 82,55,773 votes cast in favor out of 82,55,773 valid votes polled. This payout represents a dividend yield of 340% on the face value of ₹10 per share.

The meeting, conducted via Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars, also addressed key governance matters. Shareholders reappointed Dr. Davuluri Rama Mohan Rao as a Director upon his retirement by rotation and appointed Dr. Mauricio Futran as a Non-Executive Non-Independent Director. The Board’s recommendation to pay commissions to Non-Executive Directors and ratify the remuneration of Cost Auditors was also approved.

Voting Results Overview

A total of 81 members attended the meeting through VC/OAVM. The voting participation rate was approximately 64.34% of the total outstanding shares. Promoter and Promoter Group holdings accounted for 99.34% of the votes polled, while Public-Institutions contributed 84.51% of their eligible votes. Public-Non Institutions had a lower participation rate of roughly 3.08%.

Governance and Procedural Details

The AGM was chaired by Dr. D.R. Rao, Executive Chairman. Ms. Sarada Bhamidipati, Company Secretary & Compliance Officer, managed the proceedings. The Statutory and Secretarial Auditor’s Reports for FY26 contained no qualifications, observations, or adverse remarks.

Shaik Razia, Partner at D. Hanumanta Raju & Co., served as the Scrutinizer for the e-voting process conducted via the National Securities Depository Limited (NSDL) platform. Remote e-voting was open from August 1, 2026, to August 3, 2026. During the meeting, shareholders who had not voted remotely were given the opportunity to cast their votes electronically, with the facility remaining open for 15 minutes after the conclusion of the meeting.

Minor dissent was observed in the resolutions concerning the appointment of Dr. Futran and the reappointment of Dr. Rao, primarily from public institutional investors. However, all resolutions were passed with the requisite majority under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.